Amneal Pharmaceuticals (NASDAQ:AMRX) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Amneal Pharmaceuticals (NASDAQ:AMRX) released its quarterly earnings data on Thursday. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.03, Zacks reports. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. Amneal Pharmaceuticals updated its FY 2026 guidance to 0.960-1.060 EPS.

Here are the key takeaways from Amneal Pharmaceuticals’ conference call:

• Q2 results exceeded expectations and full-year guidance was raised. Revenue rose 10% to $796 million, adjusted EBITDA increased 12% to $206 million, and adjusted EPS grew 20% to $0.30. Amneal raised 2026 revenue guidance to $3.1–$3.2 billion, adjusted EBITDA guidance to $750–$780 million, and EPS guidance to $0.96–$1.06.
• The pending Kashiv acquisition is expected to create a fully integrated biosimilars platform, with more than 20 programs and potential launches including Xolair, Orencia, Cimzia, and Stelara. Management expects $400–$500 million of financial benefits from tax incentives and elimination of milestone and profit-sharing obligations, with net leverage targeted below three times by 2028.
• Specialty products continued to gain traction, with specialty revenue up 17% to $149 million. CREXONT prescriptions are increasingly coming from general neurologists, while positive Phase IV data could support management’s goal of making it a first-line Parkinson’s treatment; Brekiya also reported strong early uptake.
• Complex generics and manufacturing demand remain strong, particularly for estrogen and lidocaine patches, ophthalmics, injectables, and iohexol. Amneal expects to triple estrogen-patch capacity by next year, views iohexol as a potential $50-plus million opportunity, and anticipates a meaningful contribution beginning in 2027 from recent and expected launches such as lanreotide and lenalidomide.
• Flooding at an Amneal facility in Gujarat, India is expected to temporarily disrupt a select number of products and reduce 2026 EBITDA by approximately $20 million, although operations are expected to resume within several weeks. The company also increased 2026 capital-expenditure guidance to $140–$180 million to fund capacity expansions.

Amneal Pharmaceuticals Trading Down 3.1%

Shares of AMRX stock opened at $18.50 on Friday. Amneal Pharmaceuticals has a 12-month low of $7.66 and a 12-month high of $19.26. The business’s 50 day moving average is $16.11 and its two-hundred day moving average is $14.23. The company has a market capitalization of $5.90 billion, a P/E ratio of 48.69 and a beta of 1.26.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Barclays boosted their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. UBS Group lifted their target price on shares of Amneal Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings raised shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Finally, Zacks Research lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Amneal Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $16.60.

Insider Activity at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the sale, the director directly owned 93,660 shares in the company, valued at $1,211,960.40. The trade was a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 17.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Kemnay Advisory Services Inc. acquired a new position in Amneal Pharmaceuticals during the fourth quarter worth $26,000. Federated Hermes Inc. lifted its holdings in Amneal Pharmaceuticals by 1,680.6% during the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after purchasing an additional 2,168 shares in the last quarter. Comerica Bank grew its position in shares of Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after purchasing an additional 1,957 shares during the period. Transamerica Financial Advisors LLC grew its position in shares of Amneal Pharmaceuticals by 541.9% in the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after purchasing an additional 2,460 shares during the period. Finally, Focus Partners Wealth purchased a new stake in shares of Amneal Pharmaceuticals during the third quarter worth about $42,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

More Amneal Pharmaceuticals News

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Amneal reported $796 million in revenue, GAAP net income of $58 million, adjusted EBITDA of $206 million and adjusted diluted EPS of $0.30, versus the $0.24 consensus estimate. EPS also improved from $0.25 a year earlier. Amneal Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised or reinforced at an attractive level. Management expects 2026 revenue of $3.1 billion to $3.2 billion and EPS of $0.96 to $1.06. The EPS midpoint of $1.01 is above the roughly $0.97 analyst consensus, while the revenue midpoint of $3.15 billion is modestly above expectations. Amneal Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Debt repricing should reduce interest expense. Amneal said a July debt repricing lowered its borrowing costs, potentially supporting cash flow and future earnings. Management discussed the results and outlook during the earnings call. Amneal Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Investors may be taking profits after the initial earnings-driven rally. The results generated an immediate positive market reaction, but the stock is trading near its 52-week high. At a market capitalization of approximately $5.9 billion and a reported price-to-earnings ratio near 49, expectations for continued growth are substantial.
• Negative Sentiment: Profitability and balance-sheet metrics remain concerns. Amneal’s reported net margin was only 4.01%, and its return on equity was deeply negative. These figures may temper enthusiasm despite the earnings beat and could help explain selling pressure following the announcement.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.